BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 2043408)

  • 1. Carcinoid syndrome and somatostatin analogues.
    Varas Lorenzo M
    Rev Esp Enferm Dig; 2023 Dec; 115(12):726-727. PubMed ID: 36896924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Enteral hyperoxalosis due to therapy with a somatostatin analog].
    Ranft K; Eibl-Eibesfeldt B
    Dtsch Med Wochenschr; 1990 Feb; 115(5):179-81. PubMed ID: 2298134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
    Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
    N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SMS 201-995 and provocation tests in preparation of patients with carcinoids for surgery or hepatic arterial embolization.
    Ahlman H; Ahlund L; Dahlström A; Martner J; Stenqvist O; Tylén U
    Anesth Analg; 1988 Dec; 67(12):1142-8. PubMed ID: 2461665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of malignant carcinoid syndrome with a long-acting somatostatin analogue.
    Altman AR; Tschen JA; Rice L
    Arch Dermatol; 1989 Mar; 125(3):394-6. PubMed ID: 2923448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A prolonged-action somatostatin analog and carcinoid syndrome].
    Chayvialle JA
    Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A favorable response to the somatostatin analog SMS 201-995 in a patient with the carcinoid syndrome].
    Del Val A; Ponce J; Talens A; Martí-Bonmati L; Garrigues V; Berenguer J
    Rev Esp Enferm Dig; 1991 Mar; 79(3):215-7. PubMed ID: 2043408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of carcinoid syndrome with a somatostatin analogue].
    Döbrönte Z; Stöckert A; Végh G; Varga L
    Orv Hetil; 1992 Mar; 133(12):731-4. PubMed ID: 1372969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management.
    Vinik AI; Thompson N; Eckhauser F; Moattari AR
    Acta Oncol; 1989; 28(3):389-402. PubMed ID: 2663049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octreotide treatment of carcinoid hypertensive crisis.
    Warner RR; Mani S; Profeta J; Grunstein E
    Mt Sinai J Med; 1994 Sep; 61(4):349-55. PubMed ID: 7969229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
    Guadalupe E; Deshpande HA; Stein SM
    Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of carcinoid tumor with a long-acting somatostatin analog].
    Werling K; Lengyel G; Fehér E; Jakab Z; Besznyák I; Feher J
    Orv Hetil; 1993 Feb; 134(6):301-5. PubMed ID: 8430017
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.